A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07444541

Title field or adapter rule

{'original_value': 'A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:22.504670+00:00

Published At

2026-10-23T00:00:00+00:00

Record Updated At

2026-10-23

Source Retrieved At

2026-10-31T22:17:25.750886+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-23", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07444541"

protocolSection.identificationModule.officialTitle

"A Phase Ib/\u2161 Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['ANO31905+AG', 'ANO31905+mFOLFIRINOX'], 'description': 'ANO31905 will be administered as an IV infusion', 'name': 'ANO31905', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ANO31905+AG'], 'description': '125 mg/m\\^2 of nab-paclitaxel, intravenous infusion, D1/D8/D15 per cycle; 1000 mg/m\\^2 of gemcitabine, intravenous infusion, D1/D8/D15 per cycle until PD, intolerable toxicity or other discontinuation criteria specified in the protocol (whichever occurs first).', 'name': 'AG [gemcitabine+nab-paclitaxel]', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ANO31905+mFOLFIRINOX'], 'description': 'Oxaliplatin, 85 mg/m\\^2; irinotecan (non-liposome injection), 180 mg/m\\^2; leucovorin, 400 mg/m\\^2; and fluorouracil, 2400 mg/m\\^2 given as a 46-hour continuous infusion, on D1/D15 per cycle.', 'name': 'mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• ANO31905 (protocolSection.armsInterventionsModule.interventions[].name)
• AG [gemcitabine+nab-paclitaxel] (protocolSection.armsInterventionsModule.interventions[].name)
• mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.